Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Dentsu Inc. Q1 FY2019 Consolidated Financial Results

Published

on

Reading Time: 9 minutes

(The first quarter ended March 31, 2019 – reported on an IFRS basis)

TOKYO–(BUSINESS WIRE)–Dentsu Inc. (TOKYO:4324)(ISIN:JP3551520004):

Executive Summary

  • In Q1 FY2019, the Dentsu Group delivered total growth of revenue less
    cost of sales of 2.3% (constant currency basis) and organic growth of
    -1.6%.
  • The Japan business delivered -0.8% and -2.7% respectively, mainly due
    to a decrease in traditional media in the Japanese market, partially
    offset by digital-related services and favorable results in
    subsidiaries.
  • The international business, Dentsu Aegis Network, delivered 4.8%
    growth of revenue less cost of sales (constant currency basis) and
    -0.7% organic growth, impacted by negative growth in APAC mainly due
    to weakness in the Australian market.
  • Despite a soft start to the year, revenue is expected to build as the
    year progresses.
  • There is no change to the full-year guidance announced in February
    2019.
 

Financial Results for Q1 FY2019

Consolidated Group (million yen)   Q1

FY2019

  Q1

FY2018

  YoY

change, %

 

Constant
currency
basis, %

Revenue 250,578 242,107 3.5
Revenue less cost of sales* 227,974 226,665 0.6 2.3
Statutory results

• operating profit

9,294 22,393 (58.5)

• net profit (attributable to owners of the parent)

(2,583) 10,788

• basic EPS

(9.16) yen 38.27 yen
Underlying results**

• operating profit

24,472 32,744 (25.3) (25.2)

• operating margin

10.7% 14.4% (370) bps (390) bps

• net profit (attributable to owners of the parent)

12,551 17,972 (30.2)

• basic EPS

44.53 yen 63.76 yen (30.2)
EBITDA*** 32,201 37,022 (13.0)
Average JPY/USD rate 110.2 yen 108.3 yen 1.8
Average JPY/GBP rate   143.7 yen   150.9 yen   (4.8)  

*Revenue less cost of sales is the metric by which the Group’s
organic growth is measured. Organic growth represents the constant
currency year-on-year growth after adjusting for the effect of
businesses acquired or disposed of since the beginning of the previous
year.

** See below for definition of “underlying.”
***
See below for definition of “EBITDA.”

Highlights of Q1 FY2019 results

  • The Dentsu Group delivered growth of revenue less cost of sales of
    2.3% (constant currency basis) :

    • -0.8% in Japan, and 4.8% at Dentsu Aegis Network driven by
      acquisitions.
    • The breakdown in contribution is: +8.8 billion yen from M&As, -3.7
      billion yen by organic growth, and -3.7 billion yen from foreign
      exchange rates.
  • The Group produced organic growth of -1.6% :

    • -2.7% in Japan, and -0.7% at Dentsu Aegis Network. The Japan
      business declined due to a decrease in traditional media in the
      Japanese market, partially offset by digital-related services and
      favorable results in subsidiaries. The international business was
      impacted by negative growth in APAC, due to weakness in the
      Australian market, softer client spend and cycling out of account
      lost in FY2018.
    • Digital business contribution to total revenue less cost of
      sales
      reached 47.0% (Q1 FY2018: 43.7%), including 27.7% in
      Japan (Q1 FY2018: 23.0%), and 62.5% at Dentsu Aegis Network (Q1
      FY2018: 60.8%).
    • International business contribution to total revenue less cost
      of sales
      reached 55.5% (Q1 FY2018: 54.9%).
  • Group underlying operating profit was 24.4 billion yen (Q1
    FY2018: 32.7 billion yen).

    • 24.6 billion yen in Japan (Q1 FY2018: 30.4 billion yen), and -0.1
      billion yen at Dentsu Aegis Network (Q1 FY2018: 2.3 billion yen).
    • Difference between the underlying operating profit and statutory
      operating profit was mainly due to amortization of M&A related
      intangible assets.
  • Group underlying operating margin was 10.7% (Q1 FY2018: 14.4%).

    • 24.3% in Japan (Q1 FY2018: 29.7%), and -0.1% at Dentsu Aegis
      Network (Q1 FY2018: 1.9%).
    • The decline in Japan was mainly due to planned SG&A costs related
      to investments to drive future growth. At Dentsu Aegis Network, a
      softer-than-expected start to the year impacted on the operating
      margin which was seasonally low in the first quarter and was
      within budget.
  • Underlying net profit (attributable to owners of the parent) and
    underlying basic EPS
    decreased by 30.2% and 30.2% respectively,
    mainly due to the decline of underlying operating income and an
    increase of finance costs.

    • Difference between the underlying net profit and statutory net
      profit was mainly due to operating profit adjustments and a loss
      on M&A related put-option liabilities.

Toshihiro Yamamoto, President and CEO, Dentsu Inc., said:

“In Q1 FY2019, Dentsu Group recorded a decline in organic growth of
-1.6%, with -2.7% in Japan and -0.7% at Dentsu Aegis Network.

It
has been a soft start to the year and challenging market conditions
remain, however, we expect to see revenues build through the remainder
of the year. In Japan, a number of world-class, one-off events will
positively impact our results particularly in H2 FY2019. At Dentsu Aegis
Network, the cycling out of accounts lost in FY2018 and the on-boarding
of new business wins will begin to impact results in H2 FY2019.

In Japan, investment has continued to drive sustainable future growth
with key investments in our IT infrastructure and our digital business.
At Dentsu Aegis Network, operational excellence remains a key priority,
with the next stage focusing on client and media operation processes.

At the end of March 2019, our shareholders endorsed our plans to
reorganize the corporate structure of Dentsu Inc. effective January 1,
2020. The holding company ‘Dentsu Group Inc.’ will support all Dentsu
Group companies and our combined 62,000 talented people. The new
structure will allow for greater corporate governance and improved
integration between Dentsu in Japan and Dentsu Aegis Network.
Workstreams are already underway across many of our corporate functions
and business lines to ensure a smooth and seamless transition.

There is much to do in the remainder of the year, but through
maintaining our continued focus on driving innovation and pursuing
excellence in everything we do, I am confident we can continue to
deliver even greater value for our clients.”

Q1 FY2019 Consolidated Financial Results

1. Q1 FY2019 Performance Review

Japan:

The Group’s operations in Japan delivered organic growth of -2.7% in Q1
FY2019. This was mainly due to a decrease in traditional media in the
Japanese market, partially offset by digital-related services and
favorable results in subsidiaries.

Underlying operating margin in Japan declined by 540 bps to 24.3%. This
was mainly due to planned SG&A costs related to investments to drive
future growth.

International:

Dentsu Aegis Network delivered organic growth of -0.7% in Q1 FY2019. The
Americas reported positive organic growth, EMEA was negative but with a
mixed performance across the region and APAC (excluding Japan) was
negative, impacted by weakness in Australia.

The Q1 2019 margin is impacted by the usual seasonality expected in the
first quarter. We continue to control our costs responsibly and still
expect to deliver margin improvement in FY2019 as guided in February
2019.

Total net new business year-to-date for media is significantly ahead of
this stage last year with no major account losses. The pitch pipeline is
healthy with the current opportunities over 80% offensive. The win rate
for digital, creative & experiential is also significantly ahead of last
year’s run rate with a good spread of accounts won across all regions.

International – Regions:

In EMEA, Dentsu Aegis Network reported -0.4% organic growth in Q1
FY2019. There was a mixed performance across the region. Germany, Spain
and Italy posted double-digit growth, while Russia, Switzerland and the
Netherlands performed well. The Nordics experienced some slowdown,
facing tougher comparables after a very strong 2018, while the UK and
France were in negative territory.

In the Americas, Dentsu Aegis Network reported 0.1% organic growth in Q1
FY2019. In the U.S. the slowdown was due to timing of client spend and
the cycling out of several client accounts. Growth in the U.S. is
expected to improve in H2 FY2019 as new business wins impact our
revenues. Canada performed well while challenging macro-economic
conditions in Brazil impacted growth.

In the APAC region (excluding Japan), Dentsu Aegis Network reported
-3.0% organic growth in Q1 FY2019. Australia remains a difficult market.
A combination of macro factors and account losses cycling out will
continue to add pressure until H2 FY2019. New management has recently
joined in Australia and will continue to manage the business to reflect
the challenging operating environment we face. China returned to
positive growth in the quarter, new management has recently been
installed. There has been good growth across other markets within APAC,
including India and Thailand.

Acquisitions:

Acquisitions continue to accelerate the Group strategy by providing
innovation, scale, geographic and capability infill as well as bringing
new entrepreneurial talent into the organization. In Q1 FY2019, a total
of five new acquisitions were signed. Two acquisitions were made in
EMEA, one in the Americas and two in APAC.

In February 2019, we welcomed Happy Marketer, Southeast Asia’s leading
data-driven digital marketing agency. Joining Merkle as Happy Marketer,
a Merkle Company, this acquisition will provide a strategic foundation
for Merkle’s data, analytics and CRM solutions, enabling the delivery of
people-based marketing at scale across the region.

Note:
– IFRS 16 “Leases” is applied from January 1, 2019. Past
results are not restated under IFRS 16.

Further information

Further details of these results, including all related financial
statements, can be found in the Investor Relations section of the Dentsu
Inc. website: http://www.dentsu.com/ir.

Definitions of “underlying” and “EBITDA”

  • Underlying operating profit: KPI to measure recurring business
    performance which is calculated as operating profit added with
    amortization of M&A related intangible assets, acquisition costs,
    share-based compensation expenses related to acquired companies and
    one-off items such as gain/loss on sales and retirement of non-current
    assets and impairment loss.
  • Operating margin: Underlying operating profit divided by
    Revenue less cost of sales.
  • Underlying net profit (attributable to owners of the parent):
    KPI to measure recurring net profit attributable to owners of the
    parent which is calculated as net profit added with adjustment items
    related to operating profit, gain/loss on sales of shares of
    associates, revaluation of earnout liabilities / M&A related
    put-option liabilities, tax-related, NCI profit-related and other
    one-off items.
  • Underlying basic EPS: EPS based on underlying net profit
    (attributable to owners of the parent).
  • EBITDA: Operating profit before depreciation, amortization and
    impairment losses.
 

Reconciliation from Underlying to Statutory Operating
Profit
in Q1 FY2019

Consolidated Group (million yen)   Q1 FY2019   Q1 FY2018   Change, %
Underlying operating profit 24,472 32,744 (25.3)
Adjustment items: (15,177) (10,350)
Amortization of M&A related intangible assets (9,004) (8,792)
Acquisition costs (421) (320)
Share-based compensation expenses related to acquired companies (1,985) (1,099)
One-off items (3,767) (140)  
Statutory operating profit   9,294   22,393   (58.5)
 

Reconciliation from Underlying to Statutory Net
Profit (Loss)
in Q1 FY2019

Consolidated Group (million yen)   Q1 FY2019   Q1 FY2018   Change, %
Underlying net profit 12,551 17,972 (30.2)
Adjustment items: (15,135) (7,184)
Operating profit adjustments (15,177) (10,350)
Gain (loss) on revaluation of earnout liabilities and M&A related
put-option liabilities
(7,216) (1,918)
Related income tax expense 6,292 4,373
Adjustments attributable to non-controlling interests 967 710  
Net profit (loss)   (2,583)   10,788  
 

P/L from Statutory Operating Profit to Statutory Net Profit
(Loss) in Q1 FY2019

Consolidated Group (million yen)   Q1 FY2019   Q1 FY2018   Change, %
Operating profit 9,294 22,393 (58.5)
Share of results of associates 160 916 (82.5)
Profit before interest and tax 9,454 23,310 (59.4)
Net finance income (costs) (10,939) (4,286)
Finance income 1,302 1,502 (13.3)
Finance costs 12,241 5,789 111.4
Profit (loss) before tax (1,484) 19,023
Income tax expense (553) 6,781
Net profit (loss) (930) 12,241
Attributable to owners of the parent (2,583) 10,788
Attributable to non-controlling interests   1,652   1,453   13.6
 

Quarterly Organic Growth for the Dentsu Group, Dentsu in
Japan, and Dentsu Aegis Network

    Dentsu Group Total   Dentsu in Japan   Dentsu Aegis Network Total
2019   2018   2017* 2019   2018   2017* 2019   2018   2017*
Q1 (Jan – Mar) (1.6%) 2.1% 3.7% (2.7%) 1.9% 4.3% (0.7%) 2.2% 3.1%
Q2 (Apr – June) 5.9% (4.6%) 8.4% (7.6%) 4.5% (2.7%)
Q3 (Jul – Sept)

5.4%

(2.1%)

2.7%

(4.8%)

7.0%

(0.2%)
Q4 (Oct – Dec) 0.9% 2.8% (3.0%) 5.5% 3.4% 1.2%
Fiscal Year     3.4%   0.1%     2.1%   (0.3%)     4.3%   0.4%

* IFRS 15 “Revenue from Contracts with Customers” is applied on the
FY2017 results and their figures are adjusted.

 

Quarterly Organic Growth for Dentsu Aegis Network by region

   

Dentsu Aegis Network
EMEA

 

Dentsu Aegis Network
Americas

 

Dentsu Aegis Network
APAC

2019   2018   2017* 2019   2018   2017* 2019   2018   2017*
Q1 (Jan – Mar) (0.4%) 2.7% 5.8% 0.1% 4.6% 0.6% (3.0%) (2.9%) 4.5%
Q2 (Apr – June) 4.8% (0.3%) 6.5% (4.1%) 0.8% (3.8%)
Q3 (Jul – Sept)

8.2%

5.9%

5.3%

(2.0%)

8.2%

(5.5%)
Q4 (Oct – Dec) 12.0% 1.3% 3.5% (0.0%) (9.6%) 2.6%
Fiscal Year     7.4%   3.1%     4.9%   (1.5%)     (1.7%)   (0.6%)

* IFRS 15 “Revenue from Contracts with Customers” is applied on the
FY2017 results and their figures are adjusted.

 

FY2019 Forecasts (No change from the announcement in February
2019)

Consolidated Group
(million yen)

 

FY2019
Forecasts

 

FY2018
Actual
Results

 

YoY
change, %

 

Constant
currency
basis, %

Revenue 1,097,900 1,018,512 7.8
Revenue less cost of sales 986,400 932,680 5.8 7.9
Japan 400,800 369,258 8.5 8.5
International total 585,600 563,852 3.9 7.4
Underlying operating profit 157,400 153,229 2.7 4.3
Japan 81,300 80,268 1.3 1.3
International total 76,100 72,963 4.3 7.5
Operating margin 16.0% 16.4% (40) bps (50) bps
Japan 20.3% 21.7% (140) bps (140) bps
International total 13.0% 12.9% 10 bps 10 bps
Underlying net profit 95,400 97,419 (2.1)
Underlying basic EPS 338.42 yen 345.59 yen (2.1)
Operating profit 122,500 111,638 9.7
Net profit 61,400 90,316 (32.0)
JPY/USD rate* 109.0 yen 110.4 yen (1.3)
JPY/GBP rate*   140.7 yen   147.5 yen   (4.6)  

* FY2019 forecasts are based on average exchange rates in January
2019. Actual exchange rates in FY2018 actual results are annual average
exchange rates in 2018.

Note: Underlying net profit,
Underlying basic EPS and Net profit: Excluding attribution to
non-controlling interests.

About the Dentsu Group

Dentsu is the world’s largest advertising agency brand. Led by Dentsu
Inc. (Tokyo: 4324; ISIN: JP3551520004), a company with a history of 117
years of innovation, the Dentsu Group provides a comprehensive range of
client-centric brand, integrated communications, media and digital
services through its ten global network brands—Carat, Dentsu, dentsu X,
iProspect, Isobar, mcgarrybowen, Merkle, MKTG, Posterscope and Vizeum—as
well as through its specialist/multi-market brands. The Dentsu Group has
a strong presence in over 145 countries and regions across five
continents, and employs more than 62,000 dedicated professionals. Dentsu
Aegis Network Ltd., its international business headquarters in London,
oversees Dentsu’s agency operations outside of Japan. The Group is also
active in the production and marketing of sports and entertainment
content on a global scale. http://www.dentsu.com/

Contacts

For additional enquiries

Media –
Please contact Corporate Communications:
Tokyo
Dentsu
Inc.
Shusaku Kannan:
+81 3 6216 8042
[email protected]
London
Dentsu
Aegis Network
Dani Jordan:
+44 744 7828
[email protected]

Investors & analysts –
Please contact Investor
Relations:

Tokyo
Dentsu Inc.
Yuji Ito:
+81
3 6216 8015
[email protected]
London
Dentsu
Aegis Network
Kate Stewart:
+44 (0)203 535 8237
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Published

on

innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use

HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].

Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.

Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.

Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:

“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market

[2] https://www.cdc.gov/opioids/data/index.html

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html

Continue Reading

Curaleaf

Curaleaf Completes Acquisition of Northern Green Canada

Published

on

curaleaf-completes-acquisition-of-northern-green-canada

Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom

NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.

“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”

The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.

Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html

Continue Reading

Cannabis

Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect

Published

on

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania